Pathogenic and likely pathogenic germline variation in patients with myeloid malignancies and their unrelated HLA-matched hematopoietic stem cell donors

Abstract

Aims: The revised 2022 World Health Organization classification recognizes myeloid neoplasms with associated germline predisposition as a defined subcategory, underscoring the clinical significance of likely pathogenic (LPV) and pathogenic (PV) germline variation in these diseases. To better understand the role of LPV/PV in blood or marrow transplants (BMT), a curative therapy for myeloid neoplasms, we measure their frequency and association with mortality in two cohorts of donor-recipient pairs.

Methods: LPV/PV frequencies in 665 cancer-related genes were measured using exomechip genotyping data in 1990 acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients and their unrelated donors, registered with the Center for International Blood and Marrow Transplant Research. Cox proportional hazard models were used to test variant association with recipient mortality one-year post-transplant.

Results: Thirteen autosomal dominant (AD) LPV/PV in eight genes were found in 2.8% of patients and 2.2% of donors; those linked to autosomal recessive conditions appeared in 11.1% of patients and 11% of donors. The most common AD LPV/PV mutations in recipients were found in DDX41 (n = 18). For donors, the most frequent AD PVs occurred in CHEK2 (n = 21) and Fanconi Anemia (FA) genes (n = 7). DDX41 and CHEK2 variation did not correlate with patient survival, but patients with donors with an LPV/PVs in an FA gene had lower survival (HR = 2.38, 95%CI: 1.06-5.31, P = 0.035) than patients whose donors did not have an FA LPV/PV.

Conclusion: We identified LPVs/PVs in cancer genes in donors and recipients and are the first to show an association of donor FA PVs with mortality after BMT.

Keywords

Myeloid malignancies / blood and marrow transplant / hereditary hematologic malignancies / survival analyses / Fanconi Anemia / genetic counseling

References

[1] KlcoJM.Advances in germline predisposition to acute leukaemias and myeloid neoplasms.Nat Rev Cancer2021;21:122-37 PMCID:PMC8404376

[2] BannonSA.Hereditary predispositions to myelodysplastic syndrome.Int J Mol Sci2016;17:838 PMCID:PMC4926372

[3] LiST,WeiR.Rare germline variant contributions to myeloid malignancy susceptibility.Leukemia2020;34:1675-8 PMCID:PMC8908771

[4] ChurpekJE.Familial myelodysplastic syndrome/acute myeloid leukemia.Best Pract Res Clin Haematol2017;30:287-9 PMCID:PMC5774636

[5] ChurpekJE,BishopM,GodleyLA.Correspondence regarding the consensus statement from the worldwide network for blood and marrow transplantation standing committee on donor issues.Biol Blood Marrow Transplant2016;22:183-4

[6] University of Chicago Hematopoietic Malignancies Cancer Risk Team. How I diagnose and manage individuals at risk for inherited myeloid malignancies.Blood2016;128:1800-13 PMCID:PMC5813725

[7] NareshKN.WHO Fifth Edition Classification ProjectIntroduction to the fifth edition of the world health organization classification of tumors of hematopoietic and lymphoid tissues.Mod Pathol2023;36:100330

[8] KohlmannW.Discussing and managing hematologic germ line variants.Hematology Am Soc Hematol Educ Program2016;2016:309-15 PMCID:PMC6142475

[9] ApriliG,LombardiniL,VassanelliA.Italian Society of Transfusion Medicine and ImmunohaematologyItalian Group for Bone Marrow Transplantation working groupRecommendations for managing the donation of haematopoietic stem cells from related and unrelated donors for allogeneic transplantation.Blood Transfus2013;11:296-304 PMCID:PMC3626483

[10] ZhuQ,LiuQ.Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation.Blood2018;131:2490-9 PMCID:PMC5981168

[11] HahnT,PreusLM.Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation.EClinicalMedicine2021;40:101093 PMCID:PMC8548922

[12] HahnT,PreusL.Establishment of definitions and review process for consistent adjudication of cause-specific mortality after allogeneic unrelated-donor hematopoietic cell transplantation.Biol Blood Marrow Transplant2015;21:1679-86 PMCID:PMC4537799

[13] Ionita-LazaI,MakarovV,LinX.Sequence kernel association tests for the combined effect of rare and common variants.Am J Hum Genet2013;92:841-53 PMCID:PMC3675243

[14] KasakL,NagirnajaL.GEMINI ConsortiumBi-allelic recessive loss-of-function variants in FANCM cause non-obstructive azoospermia.Am J Hum Genet2018;103:200-12 PMCID:PMC6080835

[15] NeidhardtG,RamserJ.Association between loss-of-function mutations within the FANCM gene and early-onset familial breast cancer.JAMA Oncol2017;3:1245-8 PMCID:PMC5824291

[16] KiiskiJI,PelttariLM.FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.Breast Cancer Res Treat2017;166:217-26 PMCID:PMC5645429

[17] GodleyLA.Genetic predisposition to hematologic malignancies: management and surveillance.Blood2017;130:424-32 PMCID:PMC5533201

[18] GröbnerSN,WeischenfeldtJ.ICGC PedBrain-Seq ProjectICGC MMML-Seq ProjectThe landscape of genomic alterations across childhood cancers.Nature2018;555:321-7

[19] HuangKL,WuY.Cancer Genome Atlas Research NetworkPathogenic germline variants in 10,389 adult cancers.Cell2018;173:355-70.e14

[20] Gracia-AznarezFJ,PitaG.Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.PLoS One2013;8:e55681 PMCID:PMC3568132

[21] SlavinTP,NehorayB.Clinical Cancer Genomics Community Research Network (CCGCRN)The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.Fam Cancer2018;17:235-45 PMCID:PMC5758436

[22] ScarpaA,NonesK.Australian Pancreatic Cancer Genome InitiativeWhole-genome landscape of pancreatic neuroendocrine tumours.Nature2017;543:65-71

[23] MantereT,NurmiA.Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.Sci Rep2017;7:681 PMCID:PMC5429682

[24] SmetsersS,BristowC.Heterozygote FANCD2 mutations associated with childhood T Cell ALL and testicular seminoma.Fam Cancer2012;11:661-5

[25] ThompsonER,RylandGL.kConFabExome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles.PLoS Genet2012;8:e1002894 PMCID:PMC3459953

[26] ChurpekJE,NeistadtB.Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.Cancer2016;122:304-11 PMCID:PMC4707981

[27] KachergusJ,HulihanM.Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.Am J Hum Genet2005;76:672-80 PMCID:PMC1199304

[28] CheungM,SementinoE.Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors.Hum Mol Genet2021;30:1750-61 PMCID:PMC8411985

[29] Tatton-BrownK,LovedayC.Clinical Assessment of the Utility of Sequencing and Evaluation as a Service (CAUSES) Research StudyDeciphering Developmental Disorders (DDD) StudyThe Tatton-Brown-Rahman syndrome: a clinical study of 55 individuals with de novo constitutive DNMT3A variants.Wellcome Open Res2018;3:46 PMCID:PMC5964628

[30] LeyTJ.DNMT3A mutations in acute myeloid leukemia.Blood2011;118:SCI-31

[31] GenoveseG,HandsakerRE.Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.N Engl J Med2014;371:2477-87 PMCID:PMC4290021

[32] ChurpekJE,KanchiKL.Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.Blood2015;126:2484-90 PMCID:PMC4661171

[33] ThompsonAB,ArvaiK.Monoallelic MUTYH pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer.Fam Cancer2022;21:415-22

[34] MakishimaNannya Y, Takeda J H,TakedaJ.Clinical impacts of germline DDX41 mutations on myeloid neoplasms.Blood2020;136:38-40

[35] BannonSA,Montalban-BravoG.Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations.Front Oncol2021;10:582213 PMCID:PMC7878971

[36] QuesadaAE,DiNardoCD.DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.Am J Hematol2019;94:757-66

[37] SavageSA.Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia.Semin Hematol2017;54:105-14

[38] PrzychodzenB,SekeresMA.Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML.Oncotarget2018;9:2050-7 PMCID:PMC5788620

[39] WilliamsLS,GillisN.Donor-derived malignancy and transplantation morbidity: risks of patient and donor genetics in allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther 2023

[40] ZomerdijkN,HillGR.Adult-related haematopoietic stem cell donor experiences and the provision of information and psychosocial support: a systematic literature review.Eur J Cancer Care2019;28:e12932

[41] GragertL,WilliamsE.HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.N Engl J Med2014;371:339-48 PMCID:PMC5965695

[42] Training: genetic mutation reporting process for transplant centers. Available from: https://network.bethematchclinical.org/education/education-catalog/training-genetic-mutation-reporting-process-for-transplant-centers/ [Last accessed on 23 Jan 2024]

[43] CandeliereJ,ShorrR.Systematic scoping review of studies reporting unexpected donor-derived abnormalities from recipients of allogeneic hematopoietic cell transplantation: a proposed framework for donor disclosure.Transplant Cell Ther2022;28:408.e1-8

[44] DiNardoCD,EstecioM.Germline DNMT3A mutation in familial acute myeloid leukaemia.Epigenetics2021;16:567-76 PMCID:PMC8078744

[45] JaiswalS,FlannickJ.Age-related clonal hematopoiesis associated with adverse outcomes.N Engl J Med2014;371:2488-98 PMCID:PMC4306669

[46] CoombsCC,DevlinSM.Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes.Cell Stem Cell2017;21:374-82.e4 PMCID:PMC5591073

[47] DeZernAE.Stem cell donors should be screened for CHIP.Blood Adv2020;4:784-8 PMCID:PMC7042978

[48] GibsonCJ.Stem cell donors should not be screened for clonal hematopoiesis.Blood Adv2020;4:789-92

[49] WangY,McReynoldsLJ.Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia.Sci Rep2021;11:15004 PMCID:PMC8298542

[50] WangY,WangJ.Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT.Blood Adv2021;5:66-70 PMCID:PMC7805319

[51] TrutyR,OuyangK.Patterns of mosaicism for sequence and copy-number variants discovered through clinical deep sequencing of disease-related genes in one million individuals.Am J Hum Genet2023;110:551-64 PMCID:PMC10119133

[52] Chavarri-GuerraY,Longoria-LozanoO.Genetic cancer predisposition syndromes among older adults.J Geriatr Oncol2020;11:1054-60 PMCID:PMC7937543

[53] KaraesmenE,DileAJ.Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths.Blood Adv2019;3:2512-24 PMCID:PMC6712530

[54] KaraesmenE,PreusLM.Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.Blood2017;130:1585-96